NCT00674466View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

1.5 mg or 2.0 mg CJC-1134-PC

twice-a-week

DRUG

Placebo

twice-a-week

Trial Locations (1)

H2X 3Y8

Maggie Wang, Montreal

Sponsors

Lead Sponsor

ConjuChem
All Listed Sponsors
lead

ConjuChem

INDUSTRY